Insurers Restrict GLP-1 Access as 40% U.S. Obesity Rate Drives Billion-Dollar Cost Fears
Updated
Updated · ScienceDaily · Jul 24
Insurers Restrict GLP-1 Access as 40% U.S. Obesity Rate Drives Billion-Dollar Cost Fears
3 articles · Updated · ScienceDaily · Jul 24
Summary
GLP-1 drugs such as Ozempic, Wegovy and Zepbound remain tightly covered even though researchers say they are cost-effective, because broad uptake could add billions in insurer spending.
About 40% of Americans have obesity, and researchers said GLP-1 demand would blow past ICER's 2026 budget-impact threshold of $821 million even at relatively low uptake.
Long-term savings are still unproven: many patients stop treatment within a year because of cost, side effects or reaching target weight, and often regain weight after discontinuing.
Clinical-trial results also depended on lifestyle support alongside medication, suggesting insurers may need longer coverage plus diet, exercise and coaching services to preserve health gains.
Compounded GLP-1 alternatives may look cheaper when coverage is denied, but researchers warned they can contain unapproved or incorrect ingredients and lack FDA-level review.